Effects of losartan on left ventricular hypertrophy and plasma transforming growth factor-beta1 in elderly patients with hypertension.
- Author:
Zhen-Li WU
1
;
Ding-Li XU
;
Yang LI
;
Wen-Yan LAI
;
Peng HUANG
;
Shu-Chang BAI
;
Liang SU
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Antihypertensive Agents; therapeutic use; Female; Humans; Hypertension; blood; complications; drug therapy; Hypertrophy, Left Ventricular; blood; drug therapy; etiology; Losartan; therapeutic use; Male; Middle Aged; Transforming Growth Factor beta1; blood
- From: Journal of Southern Medical University 2009;29(3):531-533
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effects of losartan on left ventricular hypertrophy (LVH) and plasma transforming growth factor-beta1 (TGF-beta1) in elderly patients with essential hypertension (EH).
METHODSThe elderly patients with EH were divided into two groups, namely EH+LVH group and EH group according to the data of echocardiogram. The systolic and diastolic blood pressures of the patients were monitored. Plasma TGF-beta1 was measured before and after 6 months' treatment with losartan, and the relationship between TGF-beta1 and other index were analyzed.
RESULTSAfter 6 months' treatment, the blood pressure of EH+LVH group and EH group were significantly lowered (P<0.01). Significant improvement of IVSTd, LVPWd, E/A, and LVMI (P<0.01) and obvious reduction of plasma TGF-beta1 (P<0.01) occurred in EH+LVH group after 6 months' treatment. Correlation analyses indicated that the plasma TGF-beta1 level was positively correlated to LVMI (P<0.01).
CONCLUSIONLosartan can reversed LVH in elderly patients with EH partially by lowering plasma TGF-beta1 level.
